EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
NEW YORK, Sept. 07, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Insmed Incorporated (“Insmed” or the “Company”) (NASDAQ:INSM) between March 18, 2013 and June 8, 2016.
You are hereby notified that a securities class action has commenced in the USDC for the District of New Jersey. If you purchased or otherwise acquired Insmed securities between March 18, 2013 and June 8, 2016, your rights may be affected by this action. To get more information go to: http://www.zlk.com/pslra/insmed-incorporated.
The complaint alleges that, throughout the Class Period, defendants issued false and misleading statements to investors and/or failed to disclose that: (1) the data supporting Insmed’s European marketing authorization application (“MAA”) for lead product candidate ARIKAYCE was not likely to be approved by the European Medicines Agency (“EMA”) for the treatment of NTM lung disease, and (2) therefore ARIKAYCE’S approval by the EMA and subsequent commercialization in Europe were less likely and/or imminent than Insmed led investors to believe.
On June 8, 2016, Insmed announced it had withdrawn its MAA for ARIKAYCE from the EMA, revealing that the Committee for Medicinal Products for Human Use indicated that the phase 2 study did not provide a sufficient amount of evidence to support an approval.
If you suffered a loss in Insmed you have until September 13, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/pslra/insmed-incorporated.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
